Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Barry A SingerDouglas Lorne ArnoldJelena S DrulovicMark S FreedmanRalf GoldMark GudesblattElżbieta JasińskaChristopher C LaGankeRobert T NaismithDonald NegroskiJiwon OhMiguel Angel Hernandez PerezKrzysztof SelmajFlorian Then BerghAnnette WundesTjalf ZiemssenWanda Castro-BorreroHailu ChenSeth LevinMatthew ScaramozzaSai L ShankarTing WangSibyl WrayPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
DRF was generally well tolerated over 2 years, with few discontinuations due to AEs; radiological measures indicated decreased disease activity from baseline. These outcomes support DRF as a treatment option in patients with RRMS.